Breast Cancer Res. 2010;12(1):103. doi: 10.1186/bcr2463. Epub 2010 Feb 12.
Substantial reductions in breast cancer incidence in women 50 years old or older have been observed recently in many developed countries, and falling use of menopausal hormone therapy (HT) remains the most plausible explanation. In keeping with recent observations from the Women's Health Initiative, a report from the California Teachers Study cohort in this issue of Breast Cancer Research adds to this growing evidence. The investigators found a 26% reduction in invasive breast cancer in the cohort from 2000-2002 to 2003-2005, which accompanied an estimated 64% drop in HT use between 2000-2001 and 2005-2006. By collating individual data on the use of HT and breast cancer incidence, they also demonstrated that the decline in incidence was concentrated in women who had ceased HT use. The decline reflected a decrease predominantly in oestrogen receptor-positive tumours in the context of stable screening patterns over the study period. Millions of women continue to use HT, and these findings support carefully targeted short duration use as an important ongoing strategy to minimise breast cancer risk.
最近，许多发达国家的 50 岁及以上女性的乳腺癌发病率都出现了大幅下降，而绝经激素疗法（HT）的使用率下降是最合理的解释。与妇女健康倡议（Women's Health Initiative）的最新观察结果一致，本期《乳腺癌研究》（Breast Cancer Research）中来自加利福尼亚教师研究队列（California Teachers Study cohort）的一份报告进一步证实了这一不断增加的证据。研究人员发现，该队列中 2000-2002 年至 2003-2005 年期间浸润性乳腺癌发病率降低了 26%，同时 HT 的使用率估计从 2000-2001 年至 2005-2006 年期间下降了 64%。通过对 HT 使用和乳腺癌发病率的个体数据进行汇总，他们还证明发病率的下降主要集中在已经停止使用 HT 的女性中。这种下降反映了在研究期间筛查模式保持稳定的情况下，雌激素受体阳性肿瘤数量的减少。数以百万计的女性仍在使用 HT，这些发现支持短期、有针对性地使用 HT 作为降低乳腺癌风险的重要策略。
